Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Sanofi (NASDAQ: SNY) revealed the findings of the Phase III trial evaluating the effectiveness of Dupixent in babies and children aged 6 months to 5 years with unstoppable mild-to-serious atopic dermatitis. It has been disclosed that 85%to 90% of sufferers of atopic dermatitis get symptoms before the age of 5, which can often remain in maturity.
The results of Phase III confirmed that including Dupixent (dupilumab) to standard-of-care topical corticosteroids (TCS) considerably enhanced skin clearance and decreased the overall disease seriousness and itch in infants and children aged 6 months to 5 years with unstoppable moderate-to-severe atopic dermatitis.
Furthermore, Dupixent is an entirely human monoclonal antibody that suppresses the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. It was developed utilizing Regeneron’s patented VelocImmune technology. Dupixent isn’t an immunosuppressant, so it doesn’t need to be monitored in the lab.
In addition, the companies have confirmed that these results will be submitted today in a late-breaking session at the RAD 2021. The company disclosed that when it comes to treating children at such a young age, safety is more important. It is heartened by the fact that these results reveal a safety profile that matches what it has seen in other age groups. In an open-label experiment, the company will keep following these sufferers for up to 5 years.